Table 3. Inhibition of SC2 Lentivector Entrya.
Ib | c (μM)c | VE (%)d | RV (%)e | |
---|---|---|---|---|
1 | 4 | 10 | 46 ± 8 | 103 |
2 | 33 | 10 | 56 ± 12 | 107 |
3 | 11 | 50 | 4 ± 1 | 84 |
4 | 34 | 50 | 8 ± 6 | 76 |
5 | 35 | 50 | 25 ± 3 | 96f |
6 | 45 | 50 | 31 ± 3 | 81 |
7 | 36 | 50 | 34 ± 3 | 97 |
8 | 3 | 50 | 36 ± 3 | 81 |
9 | 37 | 50 | 42 ± 32 | 97f |
10 | 38 | 50 | 43 ± 26 | 37 |
11 | 39 | 50 | 52 ± 31 | 86f |
12 | 40 | 50 | 64 ± 25 | 96f |
13 | 46 | 50 | 65 ± 13 | 40f |
14 | 47 | 50 | 83 ± 12 | 70 |
15 | 41 | 5 | >100f | 100 |
16 | 48 | 5 | >100 | 94 |
17 | 49 | 5 | >100 | 92 |
18 | 16 | 5 | >100 | 89 |
19 | 42 | 10 | 97 ± 15 | 107 |
20 | 43 | 10 | 99 ± 12 | 87 |
21 | 44 | 10 | 103 ± 12 | 98 |
From normalized luminescence intensity of A549 human lung alveolar basal epithelium cells overexpressing ACE2 and TMPRSS2 after incubation with
inhibitor candidates at
concentrations c (1 h) and lentivirus with D614G SC2 spike protein (6 h), followed by 3 days for luciferase expression, reported as
vector entry (VE) in % (n = 3, ±SD).
RV: Relative cell viability. SD ≤ 10%.
SD > 10%.